Regulation of Posttranscriptional Modification as a Possible Therapeutic Approach for Retinal Neuroprotection

Understanding pathogenesis at the molecular level is the first step toward developing new therapeutic approaches. Here, we review the molecular mechanisms of visual dysfunction in two common diseases, innate chorioretinal inflammation and diabetic retinopathy, and the role of the ubiquitin-proteasom...

Full description

Saved in:
Bibliographic Details
Main Authors: Yoko Ozawa, Toshihide Kurihara, Kazuo Tsubota, Hideyuki Okano
Format: Article
Language:English
Published: Wiley 2011-01-01
Series:Journal of Ophthalmology
Online Access:http://dx.doi.org/10.1155/2011/506137
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832551340066209792
author Yoko Ozawa
Toshihide Kurihara
Kazuo Tsubota
Hideyuki Okano
author_facet Yoko Ozawa
Toshihide Kurihara
Kazuo Tsubota
Hideyuki Okano
author_sort Yoko Ozawa
collection DOAJ
description Understanding pathogenesis at the molecular level is the first step toward developing new therapeutic approaches. Here, we review the molecular mechanisms of visual dysfunction in two common diseases, innate chorioretinal inflammation and diabetic retinopathy, and the role of the ubiquitin-proteasome system (UPS) in both processes. In innate chorioretinal inflammation, interleukin-6 family ligands induce STAT3 activation in photoreceptors, which causes UPS-mediated excessive degradation of the visual substance, rhodopsin. In diabetic retinopathy, angiotensin II type 1 receptor (AT1R) signaling activates ERK in the inner layers of the retina, causing UPS-mediated excessive degradation of the synaptic vesicle protein, synaptophysin. This latter effect may decrease synaptic activity, in turn adversely affecting neuronal survival. Both mechanisms involve increased UPS activity and the subsequent excessive degradation of a protein required for visual function. Finally, we review the therapeutic potential of regulating the UPS to protect tissue function, citing examples from clinical applications in other medical fields.
format Article
id doaj-art-d8a0842d0ede464fb6bcee4829b2a0b0
institution Kabale University
issn 2090-004X
2090-0058
language English
publishDate 2011-01-01
publisher Wiley
record_format Article
series Journal of Ophthalmology
spelling doaj-art-d8a0842d0ede464fb6bcee4829b2a0b02025-02-03T06:01:46ZengWileyJournal of Ophthalmology2090-004X2090-00582011-01-01201110.1155/2011/506137506137Regulation of Posttranscriptional Modification as a Possible Therapeutic Approach for Retinal NeuroprotectionYoko Ozawa0Toshihide Kurihara1Kazuo Tsubota2Hideyuki Okano3Laboratory of Retinal Cell Biology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanLaboratory of Retinal Cell Biology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanDepartment of Ophthalmology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanDepartment of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanUnderstanding pathogenesis at the molecular level is the first step toward developing new therapeutic approaches. Here, we review the molecular mechanisms of visual dysfunction in two common diseases, innate chorioretinal inflammation and diabetic retinopathy, and the role of the ubiquitin-proteasome system (UPS) in both processes. In innate chorioretinal inflammation, interleukin-6 family ligands induce STAT3 activation in photoreceptors, which causes UPS-mediated excessive degradation of the visual substance, rhodopsin. In diabetic retinopathy, angiotensin II type 1 receptor (AT1R) signaling activates ERK in the inner layers of the retina, causing UPS-mediated excessive degradation of the synaptic vesicle protein, synaptophysin. This latter effect may decrease synaptic activity, in turn adversely affecting neuronal survival. Both mechanisms involve increased UPS activity and the subsequent excessive degradation of a protein required for visual function. Finally, we review the therapeutic potential of regulating the UPS to protect tissue function, citing examples from clinical applications in other medical fields.http://dx.doi.org/10.1155/2011/506137
spellingShingle Yoko Ozawa
Toshihide Kurihara
Kazuo Tsubota
Hideyuki Okano
Regulation of Posttranscriptional Modification as a Possible Therapeutic Approach for Retinal Neuroprotection
Journal of Ophthalmology
title Regulation of Posttranscriptional Modification as a Possible Therapeutic Approach for Retinal Neuroprotection
title_full Regulation of Posttranscriptional Modification as a Possible Therapeutic Approach for Retinal Neuroprotection
title_fullStr Regulation of Posttranscriptional Modification as a Possible Therapeutic Approach for Retinal Neuroprotection
title_full_unstemmed Regulation of Posttranscriptional Modification as a Possible Therapeutic Approach for Retinal Neuroprotection
title_short Regulation of Posttranscriptional Modification as a Possible Therapeutic Approach for Retinal Neuroprotection
title_sort regulation of posttranscriptional modification as a possible therapeutic approach for retinal neuroprotection
url http://dx.doi.org/10.1155/2011/506137
work_keys_str_mv AT yokoozawa regulationofposttranscriptionalmodificationasapossibletherapeuticapproachforretinalneuroprotection
AT toshihidekurihara regulationofposttranscriptionalmodificationasapossibletherapeuticapproachforretinalneuroprotection
AT kazuotsubota regulationofposttranscriptionalmodificationasapossibletherapeuticapproachforretinalneuroprotection
AT hideyukiokano regulationofposttranscriptionalmodificationasapossibletherapeuticapproachforretinalneuroprotection